Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Novo Nordisk A/S (NYSE:NVOGet Rating) have earned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $717.14.

Several analysts have commented on NVO shares. StockNews.com assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group upped their price target on shares of Novo Nordisk A/S from 820.00 to 860.00 in a report on Friday, November 4th. Oddo Bhf upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Thursday, September 29th. Finally, Barclays boosted their price objective on shares of Novo Nordisk A/S from 825.00 to 850.00 and gave the company an “overweight” rating in a research report on Friday, October 14th.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently modified their holdings of the business. American Research & Management Co. lifted its position in shares of Novo Nordisk A/S by 0.4% in the 2nd quarter. American Research & Management Co. now owns 24,587 shares of the company’s stock worth $2,740,000 after purchasing an additional 87 shares during the period. SRS Capital Advisors Inc. lifted its position in shares of Novo Nordisk A/S by 9.8% in the 3rd quarter. SRS Capital Advisors Inc. now owns 985 shares of the company’s stock worth $98,000 after purchasing an additional 88 shares during the period. Eukles Asset Management lifted its position in shares of Novo Nordisk A/S by 0.3% in the 2nd quarter. Eukles Asset Management now owns 29,265 shares of the company’s stock worth $3,261,000 after purchasing an additional 91 shares during the period. RFG Advisory LLC lifted its position in shares of Novo Nordisk A/S by 2.6% in the 3rd quarter. RFG Advisory LLC now owns 3,681 shares of the company’s stock worth $423,000 after purchasing an additional 92 shares during the period. Finally, Kolinsky Wealth Management LLC lifted its position in Novo Nordisk A/S by 2.6% during the third quarter. Kolinsky Wealth Management LLC now owns 3,647 shares of the company’s stock valued at $363,000 after acquiring an additional 94 shares during the last quarter. Hedge funds and other institutional investors own 6.62% of the company’s stock.

Novo Nordisk A/S Stock Up 2.1 %

NVO opened at $117.83 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.74 and a current ratio of 0.92. Novo Nordisk A/S has a fifty-two week low of $91.51 and a fifty-two week high of $122.16. The firm’s fifty day moving average is $106.80 and its 200 day moving average is $108.00. The stock has a market cap of $266.65 billion, a price-to-earnings ratio of 34.96, a price-to-earnings-growth ratio of 1.84 and a beta of 0.51.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.